Core Viewpoint - The company has successfully completed the construction and installation of equipment for its high-end new materials project and two additional industrialization projects, which are now ready for trial production [1] Group 1: Project Details - The company has initiated trial production for its "45,000 tons/year high-end new materials project" [1] - The company has also commenced trial production for the "500 tons/year hexachlorocyclotriphosphazene and 500 tons/year benzyl chloride ammonium industrialization project" [1] - Both projects have met the necessary conditions for trial production as of the announcement date [1]

股票代码：600319 股票简称：亚星化学 编号：临 2025-065 潍坊亚星化学股份有限公司关于 截至本公告披露日，公司以全资子公司潍坊亚星新材料有限公司为主体投建 的"4.5 万吨/年高端新材料项目"与"500 吨/年六氯环三磷腈和 500 吨/年苄索 氯铵产业化项目"已完成厂房建设、机器设备安装调试等各项准备工作，并符合 试生产条件。"4.5 万吨/年高端新材料项目"及"500 吨/年六氯环三磷腈和 500 吨/年苄索氯铵产业化项目"均已于近日投料试生产。 二、项目对公司的影响 上述项目符合产业政策以及公司的发展规划，项目达产后将进一步丰富园区 产业体系，提升公司持续经营能力，增强企业抵御风险实力，为公司从传统氯碱 化工向高端新材料产业转型奠定坚实基础。 三、风险提示 上述项目目前处于试生产阶段，产能爬坡并达到设计产能尚需一定时间，且 项目投产后产品品质、成本控制、市场价格等受装置适应能力、市场供需结构变 化等因素影响仍存在不确定性，进而影响公司营业收入和盈利水平。敬请广大投 资者谨慎决策，注意投资风险。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真 ...

Core Viewpoint - The company has successfully completed the construction and installation of equipment for two major projects, marking a significant step in its transition towards high-end new materials and enhancing its operational capabilities [1] Group 1: Project Details - The "45,000 tons/year high-end new materials project" and the "500 tons/year hexachlorocyclotriphosphazene and 500 tons/year benzyl chloride ammonium industrialization project" have completed all necessary preparations for trial production [1] - Both projects have recently commenced trial production, indicating readiness for operational activities [1] Group 2: Strategic Implications - These projects align with industry policies and the company's development plans, contributing to the diversification of the industrial system within the park [1] - Achieving full production capacity will enhance the company's ongoing operational capabilities and strengthen its resilience against risks, facilitating the transition from traditional chlor-alkali chemicals to high-end new materials [1]

Core Viewpoint - The company, Weifang Yaxing Chemical Co., Ltd., is undergoing a judicial auction of 13,192,797 shares held by its major shareholder, Weifang Yaxing Group Co., Ltd., which represents 3.40% of the company's total share capital [2][7]. Group 1: Auction Details - The judicial auction was initiated due to a loan dispute between Weifang Yaxing Group and Weifang Investment Group Co., Ltd. [3] - The first auction attempt on December 4-5, 2025, resulted in no successful bids, leading to a second auction scheduled for December 24-25, 2025 [3][4]. - The second auction concluded successfully on December 25, 2025, with a winning bid from a user identified as Wei Wei [4]. Group 2: Financial Aspects - The final auction price for the shares was RMB 96,977,612.19 (approximately 96.98 million) [5]. - The successful bidder is required to pay the remaining auction amount and complete the necessary procedures for the transfer of shares [5]. Group 3: Future Implications - The final outcome of the auction is subject to the confirmation by the Weifang Intermediate People's Court, and subsequent steps include payment and share transfer processes, which carry uncertainties [6][7]. - If the shares are successfully transferred, the new shareholder will be restricted from selling the shares for six months as per regulations [7].

本次被司法拍卖的标的为潍坊亚星化学股份有限公司（以下简称"公 司"或"亚星化学"） 股东潍坊亚星集团有限公司（以下简称"亚星集团"） 持有的公司 13,192,797 股无限售流通股股票。 截至本公告披露日，本次司法拍卖网拍阶段已经结束，本次拍卖的 13,192,797 股股票全部成交，占公司总股本的 3.40%。最终成交以山东省潍 坊市中级人民法院出具的拍卖成交裁定为准，本次拍卖成交股份后续还涉及 缴纳拍卖余款、股权变更过户等环节，最终结果存在不确定性。 一、本次拍卖的基本情况 公司于 2025 年 11 月 27 日披露了《关于持股 5%以上股东部分股份将被 司法拍卖的提示性公告》(公告编号：临 2025-054）。山东省潍坊市中级人民法 院立案执行公司股东潍坊亚星集团有限公司与潍坊市投资集团有限公司企业借 贷纠纷一案，在阿里巴巴司法拍卖网络平台对上述股票进行第一次网络拍卖，于 2025 年 12 月 4 日 10 时至 2025 年 12 月 5 日 10 时止公开拍卖公司 5% 以上股东潍坊亚星集团有限公司持有公司的 13,192,797 股无限售流通股股票。 2025 年 12 月 5 日，公司查询 ...

亚星化学公告称，公司股东亚星集团持有的13,192,797股无限售流通股股票司法二拍已结束，全部成 交，占总股本的3.40%。竞买人魏巍以9697.76万元竞得。最终成交以法院出具的拍卖成交裁定为准，后 续还涉及缴纳余款、股权过户等环节，结果存在不确定性。若股份完成划转，受让方6个月内不得减 持。 ...

Group 1 - The company held its 20th meeting of the 9th Board of Directors on December 23, 2025, with all 9 directors present, and the meeting was conducted in accordance with relevant laws and regulations [2][3] - The Board approved several proposals, including the change of the accounting firm, with 100% approval from the attending directors [3][10] - The proposal to change the accounting firm requires further approval from the shareholders' meeting [5][60] Group 2 - The company proposed to extend a loan of 12 million yuan from its controlling shareholder, with a maximum extension period of 10 months at an annual interest rate of 6.9%, without requiring collateral [44][47] - This loan extension constitutes a related party transaction and requires approval from the shareholders' meeting, with related shareholders abstaining from voting [45][53] - The company has previously engaged in related transactions with its controlling shareholder, including loans and other financial arrangements [48][50] Group 3 - The company’s subsidiary, Weifang Yaxing New Materials Co., Ltd., is transferring 7.1438% of its equity for 60 million yuan, with the company waiving its right of first refusal [28][29] - This transaction does not constitute a related party transaction or a major asset restructuring and will not affect the company's financial status significantly [40][30] - The transaction is part of the company's strategic adjustments and does not change its ownership structure in the subsidiary [40][29] Group 4 - The company plans to hold its first extraordinary shareholders' meeting of 2026 on January 9, 2026, with both on-site and online voting options available [14][15] - The meeting will address the proposals approved by the Board, including the change of accounting firm and the loan extension [17][18] - Shareholders must register to attend the meeting and can delegate their voting rights to a proxy [20][22] Group 5 - The company intends to change its accounting firm to Zhongshun Zhonghuan Accounting Firm, which has a strong reputation and experience in auditing public companies [59][61] - The previous accounting firm, Yongtuo, has no objections to the change, and the transition will be managed according to regulatory requirements [72][73] - The new accounting firm is expected to enhance the company's financial audit processes and internal controls [61][72]

Group 1 - The company, Yaxing Chemical, announced on December 24 that it plans to change its financial and internal control audit firm for the year 2025 from Yongtuo Accounting Firm to Zhongshen Zhonghuan Accounting Firm [2] - The audit team will consist of project partner Chen Kui, signing CPA Liu Qianqian, and quality control reviewer Huang Xiaohua [2] - The reason for the change is to comply with the rotation requirements set by the Ministry of Finance and two other departments, and to align with business needs; Yongtuo has confirmed no objections to this change, which is pending approval from the shareholders' meeting [2]

Group 1 - Jizhi Co., Ltd. plans to acquire at least 51% equity in Pumai Technology through cash payment, aiming to gain control over the company, which is a leading enterprise in the field of robot performance testing and calibration in China [1] - Yaxing Chemical's subsidiary intends to transfer 7.14% equity for 60 million yuan to another fund under the same control, indicating strategic investment movements within the same management group [2] - Weigao Bio's application for clinical trials of subcutaneous human immunoglobulin has been accepted by the National Medical Products Administration, targeting primary immunodeficiency diseases [3] Group 2 - Sentai Co., Ltd.'s controlling shareholder plans to increase shareholding by at least 100 million yuan within 12 months, aiming to enhance confidence in the company's future [4] - Health元's subsidiary has received acceptance for the marketing authorization application of Lecanemab injection, which is intended for moderate to severe plaque psoriasis patients [5][11] - Sunshine Nuohuo has signed a technical development contract for the STC008 injection project, with a total payment of 500 million yuan, indicating significant investment in cancer treatment [6] Group 3 - Hunan YN has been designated as a delivery warehouse for lithium carbonate by the Guangzhou Futures Exchange, enhancing its position in the lithium market [7] - Tianji Co., Ltd. is pushing for the industrialization of lithium sulfide material preparation, although it faces risks in commercialization [8] - Yuandong Bio has received FDA approval for Methylene Blue injection, expanding its product portfolio in the U.S. market [10] Group 4 - Nanshan Aluminum has established a wholly-owned subsidiary in Hainan with an investment of 5 million yuan, focusing on high-end aluminum products [13] - ST Xifa plans to acquire 50% equity in Lhasa Beer, aiming for full ownership, with the transaction currently in the planning stage [14] - Hengrui Medicine's SHR-A1904 injection has been included in the list of breakthrough therapy products, indicating its potential in treating advanced gastric cancer [12] Group 5 - Chengdu Gas is planning to merge three subsidiaries, streamlining operations and enhancing efficiency [26] - Baoli Electric intends to invest 50 million yuan to establish a wholly-owned subsidiary focused on key equipment and solutions in energy storage [27] - Huadian International has successfully put the second unit of its Longkou Phase IV project into commercial operation, marking a significant milestone in its energy production capacity [34]

Group 1 - The core point of the article is that Yaxing Chemical (600319.SH) announced that its subsidiary, Yaxing New Materials, will transfer 7.1438% of its equity to Green Fund for RMB 60 million [1] - The equity being transferred corresponds to a registered capital of RMB 51.436412 million [1] - The rights and obligations prior to the transfer payment settlement will remain with Jiayuan Fund, while those after the settlement will be assumed by Green Fund [1] Group 2 - The company has decided to waive its right of first refusal regarding this equity transfer [1]